查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587846

美国静脉注射注射液市场规模、份额、趋势分析报告：按产品、营养、最终用途、细分市场预测，2025-2030 年

U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals), By End-use (Home, Hospitals), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

美国静脉注射输液市场的成长与趋势：

Grand View Research最新报告显示，到2030年，美国静脉注射输液市场规模预计将达到79.1亿美元，预测期内复合年增长率为7.8%。

由于疾病盛行率的增加和外科手术数量的增加，市场正在成长。人口老化更容易罹患癌症、神经系统疾病、心血管疾病和脊椎损伤等非传染性疾病，也是市场扩张的驱动力。 2024 年 10 月，Fresenius Medical Care 宣布了一项旨在减轻透析护理中断的措施。该公司利用其全球製造设施来提高透析液和输注液的产量。在卫生与公共服务部的敦促下，费森尤斯医疗致力于透过改善生产策略来满足输液和腹膜透析 (PD) 产品的需求。

静脉静脉注射疗法可以透过补充体内电解质平衡来有效治疗严重脱水，特别是对于患有糖尿病或肾臟病等慢性病的人。主要治疗方法是生理食盐水，它是水和氯化钠的混合物。含有葡萄糖、右旋糖和左旋糖等糖的溶液也是标准溶液。 2023 年 12 月，领先的输液治疗和技术公司 Baxter 与西北医学院合作完成了输液袋回收试验的第一阶段。该计划成功避免了超过 6 吨的 PVC IV 袋最终被扔进垃圾掩埋场。这些首尾相连的袋子将遍布芝加哥，展示该计划对环境保护的贡献。

美国静脉注射输液市场报告亮点：

  • 到2024年，全肠外营养（TPN）将占总肠外营养的67.14%，因为它在为无法口服或透过胃肠道吸收的患者直接向血液提供必需营养方面发挥着重要作用。的销售份额。
  • 从营养成分来看，单剂量胺基酸溶液细分市场占据主导地位，2024年市场占有率为31.33%。这些解决方案是根据特定患者的需求量身定制的，以确保他们获得足够的氨基酸来恢復和维持身体功能。
  • 维生素和矿物质领域预计在预测期内将以最快的复合年增长率成长。这些微量营养素对于各种代谢过程和整体健康至关重要，特别是对于接受 TPN 和其他形式肠外营养的患者。
  • 就最终用途而言，医院细分市场由于其在急诊环境中的重要作用，在该细分市场中占据主导地位，到 2024 年，其市场占有率将达到 46.0%。医院是这个市场的重要参与者，因为它们需要稳定地为各种医疗程序（包括手术和医疗紧急情况）供应静脉注射输液。
  • 由于家庭治疗对患者来说更加方便且更具成本效益，家庭治疗的偏好日益增加，预计家庭治疗领域在预测期内将以最快的复合年增长率增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国静脉注射输液市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国静脉注射输液市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章美国静脉注射注射市场：产品估算及趋势分析

  • 美国静脉注射输液市场：产品仪表板
  • 美国静脉注射输液市场：产品变化分析
  • 美国静脉注射输液市场：按产品分類的收益
  • 全肠外营养（TPN）
  • 週边肠外营养（PPN）

第五章美国静脉注射市场：营养评估及趋势分析

  • 美国静脉注射输液市场：营养仪表板
  • 美国静脉注射市场：营养波动分析
  • 美国静脉注射市场：以营养分类的收益
  • 碳水化合物
  • 单剂量胺基酸
  • 维生素和矿物质
  • 肠外脂肪乳剂
  • 其他的

第六章美国静脉注射注射市场：最终用途估计和趋势分析

  • 美国静脉注射输液市场：最终用途仪表板
  • 美国静脉注射输液市场：最终用途变化分析
  • 美国静脉注射输液市场：依最终用途分類的收益
  • 家用
  • 医院
  • 点滴中心

第七章 竞争格局

  • 主要製造商的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2024年主要企业市场占有率分析
  • 公司简介
    • Fresenius Kabi AG
    • Pfizer Inc.
    • Baxter
    • B. Braun Melsungen AG
    • JW Life Science
    • ICU Medical, Inc.
    • Grifols USA, LLC
    • Amphastar Pharmaceuticals, Inc.
    • Athenex, Inc.
    • Rockwell Medical, Inc.
    • Exela Pharma Sciences, LLC
Product Code: GVR-4-68040-286-4

U.S. Intravenous Solutions Market Growth & Trends:

The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.

IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.

U.S. Intravenous Solutions Market Report Highlights:

  • The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
  • Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
  • The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
  • In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
  • The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Nutrients
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Nutrients' outlook
    • 2.2.3. End use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Aging population
      • 3.2.1.3. Advancements in medical technology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs associated with IV therapy due to shortages
      • 3.2.2.2. Risk of complications
  • 3.3. U.S. Intravenous Solutions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis

  • 4.1. Global U.S. Intravenous Solutions Market: Product Dashboard
  • 4.2. Global U.S. Intravenous Solutions Market: Product Movement Analysis
  • 4.3. Global U.S. Intravenous Solutions Market by Product, Revenue
  • 4.4. Total Parenteral Nutrition (TPN)
    • 4.4.1. Total parenteral nutrition (TPN) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Peripheral Parenteral Nutrition (PPN)
    • 4.5.1. Peripheral parenteral nutrition (PPN) market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

  • 5.1. Global U.S. Intravenous Solutions Market: Nutrients Dashboard
  • 5.2. Global U.S. Intravenous Solutions Market: Nutrients Movement Analysis
  • 5.3. Global U.S. Intravenous Solutions Market by Nutrients, Revenue
  • 5.4. Carbohydrates
    • 5.4.1. Carbohydrates market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Single Dose Amino Acids
    • 5.5.1. Single dose amino acids market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Vitamins And Minerals
    • 5.6.1. Vitamins and minerals market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Parenteral Lipid Emulsion
    • 5.7.1. Parenteral lipid emulsion market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis

  • 6.1. Global U.S. Intravenous Solutions Market: End Use Dashboard
  • 6.2. Global U.S. Intravenous Solutions Market: End Use Movement Analysis
  • 6.3. Global U.S. Intravenous Solutions Market by End Use, Revenue
  • 6.4. Home
    • 6.4.1. Home market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Hospitals
    • 6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Infusion Center
    • 6.6.1. Infusion center market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Fresenius Kabi AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Baxter
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. B. Braun Melsungen AG
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. JW Life Science
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. ICU Medical, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Grifols USA, LLC
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amphastar Pharmaceuticals, Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Athenex, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Rockwell Medical, Inc.
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Exela Pharma Sciences, LLC
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Intravenous solutions market, by type, 2018 - 2030 (USD Billion)
  • Table 3 U.S. Intravenous solutions market, by nutrients, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Intravenous solutions market, by end use, 2018-2030 (USD Billion)
  • Table 5 Participant's overview
  • Table 6 Financial performance
  • Table 7 Key companies undergoing expansions
  • Table 8 Key companies undergoing acquisitions
  • Table 9 Key companies undergoing collaborations
  • Table 10 Key companies launching new products
  • Table 11 Key companies undergoing partnerships
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. intravenous solutions market: market outlook
  • Fig. 9 U.S. intravenous solutions competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. intravenous solutions market driver impact
  • Fig. 14 U.S. intravenous solutions market restraint impact
  • Fig. 15 U.S. intravenous solutions: Product movement analysis
  • Fig. 16 U.S. intravenous solutions: Product outlook and key takeaways
  • Fig. 17 Total parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 18 Peripheral parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 19 U.S. intravenous solutions: Nutrients movement analysis
  • Fig. 20 U.S. intravenous solutions: Nutrients outlook and key takeaways
  • Fig. 21 Carbohydrates market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Single dose amino acids market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Vitamins and minerals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Parenteral lipid emulsion market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 U.S. intravenous solutions: End use movement analysis
  • Fig. 27 U.S. intravenous solutions: End use outlook and key takeaways
  • Fig. 28 Home market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Infusion center market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Key company categorization
  • Fig. 32 Strategy mapping